Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 25, 2025 08:00 ET | Source: Beyond Air™

Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and Webcast

GARDEN CITY, N.Y., July 25, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...
July 22, 2025 07:30 ET | Source: Beyond Air™

Beyond Air Awarded Therapeutic Gases Agreement with Premier, Inc.

GARDEN CITY, N.Y., July 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...
June 17, 2025 16:01 ET | Source: Beyond Air™

Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Revenues increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended March 31, 2024 Expect to report revenue of at least $1.7 million for quarter ending June 30, 2025, and...
June 16, 2025 08:00 ET | Source: Beyond Air™

Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH

LungFit PH II’s smaller, lightweight, transport-ready design is expected to open the entirety of the NO market Final design based upon substantial feedback from respiratory therapists across the...
May 20, 2025 08:00 ET | Source: Beyond Air™

Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast

GARDEN CITY, N.Y., May 20, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on...
April 24, 2025 16:05 ET | Source: Beyond Air™

Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)

GARDEN CITY, N.Y., April 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on...
April 21, 2025 16:05 ET | Source: Beyond Air™

NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism

The FDA designation marks a significant milestone in the development of a novel treatment for a rare neurodevelopmental disorder Plan to initiate first-in-human U.S. clinical trials of lead drug...
April 15, 2025 16:05 ET | Source: Beyond Air™

NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board

BOSTON, April 15, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and Alzheimer’s disease...
April 09, 2025 16:05 ET | Source: Beyond Air™

Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients’ Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home

GARDEN CITY, N.Y., April 09, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on...
April 01, 2025 08:00 ET | Source: Beyond Air™

NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer’s Disease and Reinforcing Platform’s Strength Across Neurological Disorders

BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company developing transformative treatments for complex neurological disorders, including Autism Spectrum...